Scarica l'app Stockscreener
1.58
2.60%
0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
What earnings margins imply for BioXcel Therapeutics Inc. (BX20) stockJuly 2025 Levels & Daily Momentum Trading Reports - mfd.ru
Movement Recap: Is BioXcel Therapeutics Inc. benefiting from interest rate changes2025 Top Decliners & AI Driven Stock Movement Reports - mfd.ru
Bioxcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for Igalmi in the At-Home Setting - marketscreener.com
BioXcel Therapeutics (BTAI) Advances with Igalmi for At-Home Use - GuruFocus
BioXcel Highlights IGALMI At-Home Acute Agitation Opportunity - TipRanks
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting - The Manila Times
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI in the At-Home Setting - Bitget
BioXcel Therapeutics Completes Market Assessment for IGALMI - TradingView
86M at-home agitation episodes a year: IGALMI as potential option - Stock Titan
How cyclical is BioXcel Therapeutics Inc.’s revenue streamPortfolio Gains Report & High Accuracy Buy Signal Tips - mfd.ru
Aug Selloffs: What are the risks of holding BioXcel Therapeutics Inc.Weekly Volume Report & Consistent Growth Stock Picks - mfd.ru
BioXcel Therapeutics announces milestone and retention bonuses for key executives - Investing.com
BioXcel sets milestone bonuses amid pivotal IGALMI review - TipRanks
CEO Moves: What is GMFIWs 5 year growth outlookTrade Entry Report & Community Supported Trade Ideas - baoquankhu1.vn
Rate Hike: Is BioXcel Therapeutics Inc gaining market share2025 Key Highlights & Growth Focused Entry Reports - baoquankhu1.vn
Movement Recap: Is BioXcel Therapeutics Inc. stock a falling knife or bargain buyJuly 2025 Opening Moves & Stepwise Trade Signal Guides - mfd.ru
BioXcel Says Doctor Sent Fake Email About Alzheimer's Trial - Law360
BioXcel Therapeutics submits sNDA for at-home use of IGALMI By Investing.com - Investing.com South Africa
BioXcel Therapeutics (BTAI) Advances Igalmi's Reach with FDA Sub - GuruFocus
BioXcel Therapeutics submits application to expand IGALMI use for at-home treatment - Investing.com Nigeria
BioXcel seeks FDA approval for at-home IGALMI use - TipRanks
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting - The Manila Times
BioXcel Therapeutics Submits Supplemental NDA To US FDA For IGALMI® At-Home Label Expansion - TradingView
BioXcel Therapeutics submits sNDA for at-home use of IGALMI - Investing.com
BioXcel Therapeutics Submits sNDA for IGALMI® At-Home Use - TradingView
What are the risks of holding BioXcel Therapeutics Inc.Weekly Trade Report & Capital Protection Trading Alerts - bollywoodhelpline.com
How BioXcel Therapeutics Inc. (BX20) stock moves on employment data2025 Fundamental Recap & Weekly Breakout Watchlists - bollywoodhelpline.com
Ag Plus, Inc. - Ag Plus, Inc.
Palmetto Grain Brokerage - Palmetto Grain Brokerage
1 Top Penny Stock to Watch Now - Yahoo Finance
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
BioXcel adds chief commercial officer as it prepares to expand agitation drug IGALMI’s reach - Hartford Business Journal
VIX Spike: Can BioXcel Therapeutics Inc. stock maintain growth trajectoryTrade Entry Report & Smart Swing Trading Alerts - Bộ Nội Vụ
BioXcel Therapeutics Appoints Mark Pavao as Interim Chief Commercial Officer - citybiz
Returns Recap: Is BioXcel Therapeutics Inc benefiting from interest rate changesJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
BioXcel Therapeutics names interim CCO amid IGALMI expansion - TipRanks
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting - The Manila Times
BioXcel Therapeutics Announces Interim Chief Commercial Officer - TradingView
Drugmaker taps veteran to pursue at-home treatment for bipolar agitation - Stock Titan
Published on: 2026-01-09 03:25:25 - Улправда
Oklahoma City NewsThe Oklahoman - FinancialContent
Trend Review: How institutional buying supports BioXcel Therapeutics Inc. stockJuly 2025 Spike Watch & Breakout Confirmation Trade Signals - Улправда
Will BioXcel Therapeutics Inc. stock attract ESG investorsQuarterly Portfolio Summary & Consistent Profit Alerts - ulpravda.ru
Is BioXcel Therapeutics Inc. (BX20) stock undervalued historicallyJuly 2025 Breakouts & Fast Moving Stock Trade Plans - Улправда
What insider trading reveals about BioXcel Therapeutics Inc. stockTrade Risk Assessment & Fast Entry Momentum Alerts - ulpravda.ru
How robust is BioXcel Therapeutics Inc. (BX20) stock financial positionMACD Histogram Signals & Maximize Returns With Insights - ulpravda.ru
BioXcel Seeks FDA Nod For At-Home Use Of IGALMI In Bipolar And Schizophrenia Agitation - Nasdaq
BioXcel plans FDA submission for at-home agitation treatment - Investing.com
BioXcel plans FDA submission for at-home agitation treatment By Investing.com - Investing.com Nigeria
BTAI FinancialsIncome Statement - Quiver Quantitative
BioXcel Therapeutics, Inc. Plans Supplemental NDA Submission for IGALMI® Approval for At-Home Use in Treating Agitation Associated with Bipolar Disorders and Schizophrenia - Quiver Quantitative
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI - Chartmill
BioXcel Therapeutics enacts 1-for-16 reverse stock split - MSN
BioXcel Therapeutics (BTAI) price target decreased by 26.17% to 16.12 - MSN
Will BioXcel Therapeutics Inc. stock see insider buying2025 Sector Review & Real-Time Chart Breakout Alerts - Bộ Nội Vụ
1.19%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):